Keeping it small, polar, and non-flat: diversely functionalized building blocks containing the privileged 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]- and [1,5-a]pyridine cores

被引：7

作者：

Mishchuk, Alexander ^{[1
]}

Shtil, Natalia ^{[2
]}

Poberezhnyk, Mykola ^{[3
]}

Nazarenko, Konstiantyn ^{[1
,2
]}

Savchenko, Timur ^{[1
]}

Tolmachev, Andrey ^{[1
]}

Krasavin, Mikhail ^{[4
]}

机构：

[1] Enamine Ltd, 78 Chervonotkatska, UA-02094 Kiev, Ukraine

[2] NAS Ukraine, Inst Organ Chem, 5 Murmanska Str, UA-02660 Kiev, Ukraine

[3] Taras Shevchenko Natl Univ Kyiv, 64-13 Volodymyrska St, UA-01601 Kiev, Ukraine

[4] St Petersburg State Univ, Inst Chem, Peterhof 198504, Russia

来源：

TETRAHEDRON LETTERS | 2016年 / 57卷 / 09期

基金：

俄罗斯科学基金会;

关键词：

Lead-oriented synthesis; Non-flat heterocycles; Hydrogenation; Dimroth rearrangement; Anti-diabetes drugs; DRUG DISCOVERY;

D O I：

10.1016/j.tetlet.2016.01.094

中图分类号：

O62 [有机化学];

学科分类号：

070303 ; 081704 ;

摘要：

Six sets of functionalized building blocks based on 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine as well as 5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a]pyridine cores have been prepared. These compounds are non flat, bicyclic heterocycles that are likely to find utility as privileged motifs for lead-like compound design. One set of building blocks, (5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-6-ylmethyl)amines, proved useful as a scaffold for developing compounds that stimulate glucagon-like peptide-1 (GLP-1) secretion and are novel anti-diabetes drug leads. (C) 2016 Elsevier Ltd. All rights reserved.

引用

页码：1056 / 1059

页数：4

共 24 条

[1]

[Anonymous], [No title captured], Patent No. [WO 2,006,018,727, A2, 2006018727]

[2]

[Anonymous], 2014, Janssen Pharmaceuticals, Inc, Patent No. [WO 2014111457 A1, 2014111457]

[3]

Bischoff F. P., 2014, CHEM ABSTR, V161

[4] REACTION BETWEEN ETHYL OMEGA-CHLOROALKYLIMIDATES AND HYDRAZIDES [J].

BONANOMI, M ;

BAIOCCHI, L .

JOURNAL OF HETEROCYCLIC CHEMISTRY, 1983, 20 (06) :1657-1660

[5] SYNTHESIS AND PHYSICOCHEMICAL STUDY OF 1,2,4-TRIAZOLO[4,3-A]PYRIDINES AND 1,2,4-TRIAZOLO[2,3-A]PYRIDINES [J].

BOUTEAU, B ;

LANCELOT, JC ;

ROBBA, M .

JOURNAL OF HETEROCYCLIC CHEMISTRY, 1990, 27 (06) :1649-1651

[6] Drug- and Lead-likeness, Target Class, and Molecular Diversity Analysis of 7.9 Million Commercially Available Organic Compounds Provided by 29 Suppliers [J].

Chuprina, Alexander ;

Lukin, Oleg ;

Demoiseaux, Robert ;

Buzko, Alexander ;

Shivanyuk, Alexander .

JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2010, 50 (04) :470-479

[7] Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors [J].

Edmondson, Scott D. ;

Mastracchio, Anthony ;

Cox, Jason M. ;

Eiermann, George J. ;

He, Huaibing ;

Lyons, Kathryn A. ;

Patel, Reshma A. ;

Patel, Sangita B. ;

Petrov, Aleksandr ;

Scapin, Giovanna ;

Wu, Joseph K. ;

Xu, Shiyao ;

Zhu, Bing ;

Thornberry, Nancy A. ;

Roy, Ranabir Sinha ;

Weber, Ann E. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (15) :4097-4101

[8] Pursuing the leadlikeness concept in pharmaceutical research [J].

Hann, MM ;

Oprea, TI .

CURRENT OPINION IN CHEMICAL BIOLOGY, 2004, 8 (03) :255-263

[9] The re-emergence of natural products for drug discovery in the genomics era [J].

Harvey, Alan L. ;

Edrada-Ebel, RuAngelie ;

Quinn, Ronald J. .

NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (02) :111-129

[10] PYRIDINE RING NUCLEOPHILIC RECYCLIZATIONS [J].

KOST, AN ;

GROMOV, SP ;

SAGITULLIN, RS .

TETRAHEDRON, 1981, 37 (20) :3423-3454

← 1 2 3 →